1
|
Margolis N, Moalem H, Meirson T, Galore-Haskel G, Markovits E, Baruch EN, Vizel B, Yeffet A, Kanterman-Rifman J, Debby A, Besser MJ, Schachter J, Markel G. Adenosine-deaminase-acting-on-RNA-1 facilitates T-cell migration toward human melanoma cells. Cancer Immunol Res 2022; 10:1127-1140. [PMID: 35731225 DOI: 10.1158/2326-6066.cir-21-0643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 01/10/2022] [Accepted: 06/14/2022] [Indexed: 11/16/2022]
Abstract
The effect of tumor/T-cell interactions on subsequent immune infiltration is undefined. Here we report that pre-exposure of melanoma cells to cognate T cells enhanced the chemotaxis of new T cells in vitro. The effect was HLA class I-restricted and IFNγ-dependent, as it was abolished by β2M-knockdown, MHC-blocking antibodies, JAK1 inhibitors, JAK1-silencing and IFNgR1-blocking antibodies. RNA-sequencing of 73 melanoma metastases showed a significant correlation between the interferon-inducible p150 isoform of adenosine-deaminase-acting-on-RNA-1 (ADAR1) enzyme and immune infiltration. Consistent with this, co-cultures of cognate melanoma/T-cell pairs led to IFNγ-dependent induction of ADAR1-p150 in the melanoma cells, as visualized in situ using dynamic cell blocks, in ovo using fertilized chick eggs, and in vitro with Western blots. ADAR1 staining and RNA-sequencing in patient-derived biopsies following immunotherapy showed a rise in ADAR1-p150 expression concurrently with CD8+ cell infiltration and clinical response. Silencing ADAR1-p150 abolished the IFNγ-driven enhanced T-cell migration, confirming its mechanistic role. Silencing and overexpression of the constitutive isoform of ADAR1, ADAR1-p110, decreased and increased T-cell migration, respectively. Chemokine arrays showed that ADAR1 controls the secretion of multiple chemokines from melanoma cells, probably through microRNA-mediated regulation. Chemokine receptor blockade eliminated the IFNγ-driven T-cell chemotaxis. We propose that the constitutive ADAR1 downregulation observed in melanoma contributes to immune exclusion, whereas antigen-specific T cells induce ADAR1-p150 by releasing IFNγ, which can drive T-cell infiltration.
Collapse
Affiliation(s)
| | - Hanna Moalem
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | | | | | | | - Erez N Baruch
- The University of Texas Health Science Center at Houston, Houston, TX, United States
| | - Bella Vizel
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | | | | | | | | | | | - Gal Markel
- Rabin Medical Center, Petah Tikva, Israel
| |
Collapse
|
2
|
Galore-Haskel G, Greenberg E, Yahav I, Markovits E, Ortenberg R, Shapira-Fromer R, Itzhaki O, Schachter J, Besser MJ, Markel G. microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. Cancer Immunol Immunother 2021; 70:1541-1555. [PMID: 33201337 DOI: 10.1007/s00262-020-02782-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Accepted: 10/24/2020] [Indexed: 10/23/2022]
Abstract
Adoptive cell transfer (ACT) using autologous tumor infiltrating lymphocytes (TILs) was previously shown to yield clinical response in metastatic melanoma patients as an advanced line. Unfortunately, there is no reliable marker for predicting who will benefit from the treatment. We analyzed TIL samples from the infusion bags used for treatment of 57 metastatic melanoma patients and compared their microRNA profiles. The discovery cohort included six responding patients and seven patients with progressive disease, as defined by RECIST1.1. High throughput analysis with NanoString nCounter demonstrated significantly higher levels of miR-34a-5p and miR-22-3p among TIL from non-responders. These results were validated in TIL infusion bag samples from an independent cohort of 44 patients, using qRT-PCR of the individual microRNAs. Using classification trees, a data-driven predictive model for response was built, based on the level of expression of these microRNAs. Patients that achieved stable disease were classified with responders, setting apart the patients with progressive disease. Moreover, the expression levels of miR-34a-5p in the infused TIL created distinct survival groups, which strongly supports its role as a potential biomarker for TIL-ACT therapy. Indeed, when tested against autologous melanoma cells, miRLow TIL cultures exhibited significantly higher cytotoxic activity than miRHigh TIL cultures, and expressed features of terminally exhausted effectors. Finally, overexpression of miR-34a-5p or miR-22-3p in TIL inhibited their cytotoxic ability in vitro. Overall, we show that a two-microRNA signature correlates with failure of TIL-ACT therapy and survival in melanoma patients.
Collapse
Affiliation(s)
- Gilli Galore-Haskel
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel
| | - Eyal Greenberg
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel
| | - Inbal Yahav
- Graduate School of Business Administration, Tel Aviv University, Tel Aviv, Israel
| | - Ettai Markovits
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel.,Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Rona Ortenberg
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel
| | - Ronnie Shapira-Fromer
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel
| | - Orit Itzhaki
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel
| | - Jacob Schachter
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel.,Sackler School of Medicine and Tel Aviv University, Tel Aviv, Israel
| | - Michal J Besser
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel.,Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gal Markel
- Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 526260, Israel. .,Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
| |
Collapse
|
3
|
Galore-Haskel G, Baruch EN, Berg AL, Barshack I, Zilinsky I, Avivi C, Besser MJ, Schachter J, Markel G. Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma. Oncotarget 2017; 8:99580-99586. [PMID: 29245925 PMCID: PMC5725116 DOI: 10.18632/oncotarget.20884] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 07/11/2017] [Indexed: 12/18/2022] Open
Abstract
Intercellular adhesion molecule 1 (ICAM-1) protein is an important adhesion molecule that facilitates metastasis on one hand, and on the other hand supports the immunological synapse necessary for T-cell mediated elimination. The expression pattern of ICAM-1 in melanoma was studied more than two decades ago, mainly in cell lines or in unmatched melanoma specimens. By using real time PCR we could not demonstrate a clear difference in ICAM-1 mRNA levels between primary melanocytes and primary cultures of metastatic melanoma. However, immunohistochemistry staining of progression tissue microarray comprised of samples of different disease stages derived from different patients, demonstrated a dramatic ICAM-1 upregulation particularly upon the transition from primary tumor to lymph node metastasis. There was no significant difference between lymph node and distant metastases. Importantly, these results were confirmed in an independent tissue microarray comprised of patient-paired specimens from progressive stages of the patient’s disease. These data indicate that ICAM-1 upregulation is required to initiate the lymphatic spread of melanoma (Stage III) but no further increase is associated with progression to remote organs (Stage IV).
Collapse
Affiliation(s)
| | - Erez N Baruch
- Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel.,Clinical Microbiology and Immunology, Tel-Aviv, Israel
| | - Amy L Berg
- Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel
| | - Iris Barshack
- Institute of Pathology, Ramat-Gan, Israel.,School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | - Itzhak Zilinsky
- School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.,Department of Plastic and Reconstructive Surgery, Ramat-Gan, Israel
| | | | - Michal J Besser
- Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel.,Clinical Microbiology and Immunology, Tel-Aviv, Israel
| | - Jacob Schachter
- Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel.,School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
| | - Gal Markel
- Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel.,Clinical Microbiology and Immunology, Tel-Aviv, Israel.,Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel
| |
Collapse
|
4
|
Markel G, Imazio M, Koren-Morag N, Galore-Haskel G, Schachter J, Besser M, Cumetti D, Maestroni S, Altman A, Shoenfeld Y, Brucato A, Adler Y. CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis. Oncotarget 2017; 7:17885-95. [PMID: 26909604 PMCID: PMC4951257 DOI: 10.18632/oncotarget.7530] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2015] [Accepted: 01/23/2016] [Indexed: 11/25/2022] Open
Abstract
Background The immune response plays a significant role in pericarditis, but the mechanisms of disease are poorly defined. Further, efficient monitoring and predictive clinical tools are unavailable. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is an immune-inhibitory protein, while MHC class I chain related protein A (MICA) and B (MICB) have an immune-stimulating function. Methods and results Serum CEACAM1, MICA and MICB concentrations were measured by ELISA in ∼50 subjects of each group: acute pericarditis (AP), recurrent pericarditis (RP) and lupus (SLE) patients, metastatic melanoma patients as well as healthy donors. Serum CEACAM1 was dramatically elevated in AP and RP patients, but not in SLE patients, and displayed a highly accurate profile in ROC curve analyses. MICA and MICB were elevated in some pericarditis patients. All markers were enhanced in metastatic melanoma patients irrespective of neoplastic pericardial involvement. Etiology-guided analysis of RP patients showed that very low MICA levels were associated with idiopathic RP, while high MICA was associated with autoimmune and post-operative RP. Importantly, MICA was significantly associated with recurrences, independently of other potentially confounding parameters such as age, time of follow up or treatment modality. Conclusions Here we report for the first time on CEACAM1 as a potentially novel biomarker for pericarditis, as well as on MICA as an innovative prognostic marker in these patients. Determination of the roles of these immune factors, as well as their diagnostic and prognostic values should be determined in future prospective studies.
Collapse
Affiliation(s)
- Gal Markel
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel.,Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Israel.,Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Massimo Imazio
- Cardiology Department, Maria Vittoria Hospital, Torino, Italy
| | - Nira Koren-Morag
- Department of Epidemiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gilli Galore-Haskel
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
| | - Jacob Schachter
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
| | - Michal Besser
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel.,Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | | | - Arie Altman
- Internal Medicine B, Sheba Medical Center, Tel Hashomer, Israel
| | - Yehuda Shoenfeld
- Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
| | | | - Yehuda Adler
- Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Israel.,Cardiac Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, Israel.,Department of Internal Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
5
|
Haik J, Nardini G, Goldman N, Galore-Haskel G, Harats M, Zilinsky I, Weissman O, Schachter J, Winkler E, Markel G. Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burns. Oncotarget 2016; 7:2220-8. [PMID: 26745675 PMCID: PMC4823030 DOI: 10.18632/oncotarget.6789] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2015] [Accepted: 12/23/2015] [Indexed: 11/25/2022] Open
Abstract
Immune suppression following major thermal injury directly impacts the recovery potential. Limited data from past reports indicate that natural killer cells might be suppressed due to a putative soluble factor that has remained elusive up to date. Here we comparatively study cohorts of patients with Major and Non-Major Burns as well as healthy donors. MICB and ULBP1 are stress ligands of NKG2D that can be induced by heat stress. Remarkably, serum concentration levels of MICB and ULBP1 are increased by 3-fold and 20-fold, respectively, already within 24h post major thermal injury, and are maintained high for 28 days. In contrast, milder thermal injuries do not similarly enhance the serum levels of MICB and ULBP1. This kinetics coincides with a significant downregulation of NKG2D expression among peripheral blood NK cells. Downregulation of NKG2D by high concentration of soluble MICB occurs in cancer patients and during normal pregnancy due to over production by cancer cells or extravillous trophoblasts, respectively, as an active immune-evasion mechanism. In burn patients this seems an incidental outcome of extensive thermal injury, leading to reduced NKG2D expression. Enhanced susceptibility of these patients to opportunistic viral infections, particularly herpes viruses, could be explained by the reduced NKG2D expression. Further studies are warranted for translation into innovative diagnostic or therapeutic technologies.
Collapse
Affiliation(s)
- Josef Haik
- Department of Plastic Surgery, Tel Aviv University, Tel Aviv, Israel.,Talpiot Medical Leadership Program, Tel Aviv University, Tel Aviv, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gil Nardini
- Department of Plastic Surgery, Tel Aviv University, Tel Aviv, Israel
| | - Noga Goldman
- Department of General Surgery C, Tel Aviv University, Tel Aviv, Israel
| | | | - Moti Harats
- Department of Plastic Surgery, Tel Aviv University, Tel Aviv, Israel
| | - Isaac Zilinsky
- Department of Plastic Surgery, Tel Aviv University, Tel Aviv, Israel
| | - Oren Weissman
- Department of Plastic Surgery, Tel Aviv University, Tel Aviv, Israel
| | - Jacob Schachter
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel
| | - Eyal Winkler
- Department of Plastic Surgery, Tel Aviv University, Tel Aviv, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gal Markel
- Talpiot Medical Leadership Program, Tel Aviv University, Tel Aviv, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel
| |
Collapse
|
6
|
Galore-Haskel G, Nemlich Y, Greenberg E, Ashkenazi S, Hakim M, Itzhaki O, Shoshani N, Shapira-Fromer R, Ben-Ami E, Ofek E, Anafi L, Besser MJ, Schachter J, Markel G. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget 2015; 6:28999-9015. [PMID: 26338962 PMCID: PMC4745707 DOI: 10.18632/oncotarget.4905] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Accepted: 08/10/2015] [Indexed: 12/21/2022] Open
Abstract
The blossom of immunotherapy in melanoma highlights the need to delineate mechanisms of immune resistance. Recently, we have demonstrated that the RNA editing protein, adenosine deaminase acting on RNA-1 (ADAR1) is down-regulated during metastatic transition of melanoma, which enhances melanoma cell proliferation and tumorigenicity. Here we investigate the role of ADAR1 in melanoma immune resistance.Importantly, knockdown of ADAR1 in human melanoma cells induces resistance to tumor infiltrating lymphocytes in a cell contact-dependent mechanism. We show that ADAR1, in an editing-independent manner, regulates the biogenesis of miR-222 at the transcription level and thereby Intercellular Adhesion Molecule 1 (ICAM1) expression, which consequently affects melanoma immune resistance. ADAR1 thus has a novel, pivotal, role in cancer immune resistance. Corroborating with these results, the expression of miR-222 in melanoma tissue specimens was significantly higher in patients who had no clinical benefit from treatment with ipilimumab as compared to patients that responded clinically, suggesting that miR-222 could function as a biomarker for the prediction of response to ipilimumab.These results provide not only novel insights on melanoma immune resistance, but also pave the way to the development of innovative personalized tools to enable optimal drug selection and treatment.
Collapse
Affiliation(s)
- Gilli Galore-Haskel
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
- Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
| | - Yael Nemlich
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
| | - Eyal Greenberg
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
- Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
| | - Shira Ashkenazi
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
- Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
| | - Motti Hakim
- cCAM Biotherapeutics, Misgav Industrial Park, Misgav, Israel
| | - Orit Itzhaki
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
| | - Noa Shoshani
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
| | | | - Eytan Ben-Ami
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
| | - Efrat Ofek
- Institute of Pathology, Sheba Medical Center, Israel
| | - Liat Anafi
- Institute of Pathology, Sheba Medical Center, Israel
| | - Michal J. Besser
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
- Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
| | - Jacob Schachter
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
| | - Gal Markel
- Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Israel
- Talpiot Medical Leadership Program, Sheba Medical Center, Israel
- Department of Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
7
|
Markel G, Galore-Haskel G, Sullivan R. Highlights from the latest articles in pharmacogenomics research. Pharmacogenomics 2014; 15:1063-4. [PMID: 25084199 DOI: 10.2217/pgs.14.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Gal Markel
- Tel Aviv University, Ramat Aviv, 6997801, Israel
| | | | | |
Collapse
|
8
|
Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler Y, Zan-Bar I, Besser MJ, Azizi E, Eitan F, Schachter J, Markel G. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia 2014; 16:451-60. [PMID: 24931667 PMCID: PMC4198694 DOI: 10.1016/j.neo.2014.05.003] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The prognostic value of the carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) in melanoma was demonstrated more than a decade ago as superior to Breslow score. We have previously shown that intercellular homophilic CEACAM1 interactions protect melanoma cells from lymphocyte-mediated elimination. Here, we study the direct effects of CEACAM1 on melanoma cell biology. By employing tissue microarrays and low-passage primary cultures of metastatic melanoma, we show that CEACAM1 expression gradually increases from nevi to metastatic specimens, with a strong dominance of the CEACAM1-Long tail splice variant. Using experimental systems of CEACAM1 knockdown and overexpression of selective variants or truncation mutants, we prove that only the full-length long tail variant enhances melanoma cell proliferation in vitro and in vivo. This effect is not reversed with a CEACAM1-blocking antibody, suggesting that it is not mediated by intercellular homophilic interactions. Downstream, CEACAM1-Long increases the expression of Sox-2, which we show to be responsible for the CEACAM1-mediated enhanced proliferation. Furthermore, analysis of the CEACAM1 promoter reveals two single-nucleotide polymorphisms (SNPs) that significantly enhance the promoter's activity compared with the consensus nucleotides. Importantly, case-control genetic SNP analysis of 134 patients with melanoma and matched healthy donors show that patients with melanoma do not exhibit the Hardy-Weinberg balance and that homozygous SNP genotype enhances the hazard ratio to develop melanoma by 35%. These observations shed new mechanistic light on the role of CEACAM1 in melanoma, forming the basis for development of novel therapeutic and diagnostic technologies.
Collapse
Affiliation(s)
- Rona Ortenberg
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gilli Galore-Haskel
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ilanit Greenberg
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel
| | - Bella Zamlin
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Sivan Sapoznik
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel
| | - Eyal Greenberg
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Iris Barshack
- Institute of Pathology, Sheba Medical Center, Ramat-Gan 526260, Israel
| | - Camila Avivi
- Institute of Pathology, Sheba Medical Center, Ramat-Gan 526260, Israel
| | - Yulia Feiler
- Cancer Research Center, Sheba Medical Center, Ramat-Gan, Israel
| | - Israel Zan-Bar
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Michal J Besser
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ester Azizi
- Department of Dermatology, Sheba Medical Center, Ramat-Gan, Israel
| | - Friedman Eitan
- The Susanne-Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Ramat-Gan, Israel
| | - Jacob Schachter
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel
| | - Gal Markel
- Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel.
| |
Collapse
|
9
|
Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother 2012; 61:1833-47. [PMID: 22441657 PMCID: PMC11028868 DOI: 10.1007/s00262-012-1245-1] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2011] [Accepted: 03/06/2012] [Indexed: 10/28/2022]
Abstract
Adoptive cell transfer therapy with reactive T cells is one of the most promising immunotherapeutic modalities for metastatic melanoma patients. Homing of the transferred T cells to all tumor sites in sufficient numbers is of great importance. Here, we seek to exploit endogenous chemotactic signals in order to manipulate and enhance the directional trafficking of transferred T cells toward melanoma. Chemokine profiling of 15 melanoma cultures shows that CXCL1 and CXCL8 are abundantly expressed and secreted from melanoma cultures. However, the complimentary analysis on 40 melanoma patient-derived tumor-infiltrating lymphocytes (TIL) proves that the corresponding chemokine receptors are either not expressed (CXCR2) or expressed at low levels (CXCR1). Using the in vitro transwell system, we demonstrate that TIL cells preferentially migrate toward melanoma and that endogenously expressing CXCR1 TIL cells are significantly enriched among the migrating lymphocytes. The role of the chemokines CXCL1 and CXCL8 is demonstrated by partial abrogation of this enrichment with anti-CXCL1 and anti-CXCL8 neutralizing antibodies. The role of the chemokine receptor CXCR1 is validated by the enhanced migration of CXCR1-engineered TIL cells toward melanoma or recombinant CXCL8. Cytotoxicity and IFNγ secretion activity are unaltered by CXCR1 expression profile. Taken together, these results mark CXCR1 as a candidate for genetic manipulations to enhance trafficking of adoptively transferred T cells. This approach is complimentary and potentially synergistic with other genetic strategies designed to enhance anti-tumor potency.
Collapse
Affiliation(s)
- Sivan Sapoznik
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
| | - Rona Ortenberg
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
- Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gilli Galore-Haskel
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
- Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Stav Kozlovski
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
- Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Daphna Levy
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
| | - Camila Avivi
- Institute of Pathology, Sheba Medical Center, Ramat Gan, Israel
| | - Iris Barshack
- Institute of Pathology, Sheba Medical Center, Ramat Gan, Israel
- Pathology Department, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Cyrille J. Cohen
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
| | - Michal J. Besser
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
- Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Jacob Schachter
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
| | - Gal Markel
- The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
- Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel
- Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
10
|
Galore-Haskel G, Azizi E, Mohamdi H, Scope A, Chaudru V, Laitman Y, Barak F, Pavlotsky F, Demenais F, Friedman E. MC1R variant alleles and malignant melanoma risk in Israel. Eur J Cancer 2009; 45:2015-22. [DOI: 10.1016/j.ejca.2009.02.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2008] [Revised: 02/02/2009] [Accepted: 02/02/2009] [Indexed: 10/21/2022]
|
11
|
Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, Barak F, Cohen OS, Friedman E. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 2009; 256:483-7. [PMID: 19412725 DOI: 10.1007/s00415-009-0117-x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2008] [Revised: 09/02/2008] [Accepted: 09/25/2008] [Indexed: 11/29/2022]
Abstract
BACKGROUND A single missense mutation (G2019S) in the leucine rich repeat kinase 2 (LRRK2) gene has been reported to be prevalent among Ashkenazi Jewish patients with Parkinson disease (PD). An association between malignant melanoma (MM) and PD was also recently reported. The nature of this association is still elusive. OBJECTIVE To evaluate the rate of the G2019S(*) LRKK2 mutation among ethnically diverse, Jewish PD patients, MM patients, and Ashkenazi, Iraqi and Moroccan healthy controls. PATIENTS AND METHODS Overall, 242 Jewish PD patients (155 Ashkenazim and 7 of mixed origin) and 169 Jewish MM patients (142 Ashkenazim) were genotyped for the G2019S mutation. In addition, 900 healthy ethnic Jewish controls (300 Ashkenazim, 300 Moroccans and 300 Iraqis) were similarly analyzed. Genotyping was performed using PCR amplification followed by restriction digest and gel electrophoresis. Statistical analysis was done using the Chi square test. RESULTS Overall 19/242 (7.9 %) of the PD patients (16/155 of Ashkenazim, 10.3 %; 3/87 of non-Ashkenazim, 3.4 %) harbored the G2019S LRKK2 mutation. The age at diagnosis of PD in mutation carriers was 60.6 +/- 10.9 years compared with an age at diagnosis of 61.1 +/- 13.4 years in non-carriers (p = 0.87). Nine of 38 familial Ashkenazi PD patients (23.68 %) carried the mutation, as did 2/169 MM patients (1.2 %; 2/142, 1.4 % of the Ashkenazim). A single mutation carrier of Ashkenazi origin was detected among 900 controls (0.3 % of the Ashkenazi controls). CONCLUSION The G2019S*LRKK2 mutation is significantly more prevalent in Ashkenazi PD patients than in controls (p = 1 x 10(-6)), it is less commonly detected in non-Ashkenazi affected individuals, and its contribution to MM predisposition in Jewish individuals needs to be explored further.
Collapse
Affiliation(s)
- Sharon Hassin-Baer
- The Parkinson's Disease and Movement Disorders Clinic, Dept. of Neurology and Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel.
| | | | | | | | | | | | | | | |
Collapse
|